Last 24 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -13.98 | — | — | — | — | — | 64.10 | — | 96.07 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.36 | 4.39 | 4.46 | 4.61 | 7.23 | 6.64 | 6.69 | 7.15 | 5.42 | 3.74 | 2.47 | 0.95 | 0.31 | 0.44 | 0.78 | 1.40 | 0.42 | 1.00 | 2.94 | 3.48 | 4.66 |
| — | -34.0% | -33.4% | -35.6% | +33.3% | +77.7% | +171.1% | +650.8% | +1643.5% | +749.4% | +217.2% | -32.0% | -25.6% | -56.1% | -73.6% | -59.7% | -91.0% | -89.1% | -78.7% | -67.7% | -41.9% | |
| P/B Ratio | 4.53 | 8.83 | 8.35 | 7.41 | 11.35 | 10.62 | 9.91 | 9.69 | 8.46 | 5.62 | 3.59 | 1.15 | 0.31 | 0.37 | 0.51 | 0.74 | 0.40 | 0.60 | 0.67 | 2.28 | 2.78 |
| — | -16.8% | -15.7% | -23.5% | +34.1% | +88.8% | +176.4% | +743.5% | +2600.1% | +1423.1% | +600.9% | +56.0% | -22.5% | -38.0% | -23.4% | -67.7% | -85.4% | -85.4% | — | — | -99.4% | |
| P/FCF | — | — | — | — | — | 80.84 | 85.29 | 153.78 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | 242.00 | 45.98 | 556.39 | 36.65 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | 61.22 | — | 86.13 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.7% | 69.9% | 68.4% | 66.7% | 65.2% | 72.4% | 69.0% | 67.1% | 69.2% | 62.2% | 60.9% | 59.9% | 53.6% | 47.4% | 38.5% | 35.3% | -26.6% | 16.3% | -81.8% | 10.4% | 15.9% |
| — | -3.4% | -1.0% | -0.6% | -5.8% | +16.4% | +13.3% | +12.0% | +29.2% | +31.3% | +58.2% | +69.7% | +301.3% | +191.1% | +147.1% | +238.7% | -267.2% | +184.6% | -3205.3% | +254.9% | +2352.6% | |
| Operating Margin | -2.8% | -8.5% | -15.3% | -25.6% | -11.3% | -2.8% | 8.7% | -5.2% | 9.2% | -10.1% | -15.0% | -21.9% | -44.7% | -80.6% | -106.0% | -139.9% | -529.6% | -109.1% | -449.7% | -165.6% | -200.7% |
| — | -204.2% | -274.8% | -390.2% | -223.2% | +72.5% | +158.2% | +76.1% | +120.6% | +87.4% | +85.8% | +84.4% | +91.6% | +26.1% | +76.4% | +15.5% | -163.8% | +46.6% | -365.2% | +46.0% | -2.7% | |
| Net Margin | -4.9% | -10.0% | -15.5% | -61.9% | -14.6% | -6.5% | 10.5% | -7.5% | 5.7% | -10.8% | -41.4% | -32.4% | -44.9% | -79.3% | -95.9% | -141.4% | -503.3% | -93.2% | -237.1% | -142.6% | -69.9% |
| — | -53.1% | -247.3% | -726.2% | -356.8% | +39.5% | +125.4% | +76.9% | +112.7% | +86.4% | +56.9% | +77.1% | +91.1% | +14.9% | +59.5% | +0.8% | -619.6% | -223.0% | -141.4% | +52.3% | +64.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.6% | -5.0% | -7.1% | -22.5% | -5.9% | -2.7% | 4.0% | -2.6% | 2.4% | -4.2% | -14.5% | -9.3% | -10.7% | -15.4% | -15.0% | -21.0% | -75.8% | -12.9% | -17.7% | -21.4% | -10.4% |
| — | -88.0% | -276.0% | -766.9% | -343.3% | +35.7% | +127.8% | +72.1% | +122.6% | +72.9% | +2.8% | +55.6% | +85.9% | -18.7% | +15.7% | +2.2% | -630.4% | -131.8% | — | — | +99.6% | |
| ROA | -4.5% | -2.4% | -3.6% | -11.8% | -3.3% | -1.6% | 2.4% | -1.5% | 1.3% | -2.1% | -7.4% | -5.0% | -6.2% | -9.5% | -9.1% | -11.2% | -44.9% | -8.8% | -11.8% | -14.3% | -7.0% |
| — | -53.4% | -251.3% | -680.0% | -352.8% | +23.5% | +131.9% | +69.7% | +121.3% | +78.0% | +18.6% | +55.5% | +86.3% | -7.5% | +22.6% | +22.1% | -543.3% | -204.8% | +49.4% | +82.4% | +86.0% | |
| ROIC | -3.0% | -2.2% | -3.9% | -5.7% | -3.1% | -0.8% | 2.3% | -1.2% | 2.5% | -2.3% | -3.2% | -4.1% | -7.9% | -14.2% | -19.1% | -23.6% | -76.0% | -15.5% | -47.0% | -123.6% | — |
| — | -181.1% | -269.1% | -361.9% | -226.3% | +65.5% | +172.0% | +70.0% | +131.1% | +84.1% | +83.5% | +82.5% | +89.6% | +8.6% | +59.3% | +80.9% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.88 | 0.69 | 0.66 | 0.49 | 0.39 | 0.41 | 0.45 | 0.47 | 0.57 | 0.60 | 0.59 | 0.53 | 0.29 | 0.25 | 0.23 | 0.30 | 0.14 | 0.12 | 0.22 | 0.08 |
| — | +127.3% | +66.1% | +48.4% | +4.1% | -31.8% | -31.5% | -25.0% | -9.8% | +96.1% | +136.9% | +159.3% | +72.8% | +108.4% | +106.4% | +2.7% | +259.2% | +394.2% | — | — | -99.1% | |
| Debt / EBITDA | 8.43 | — | — | — | — | 35.11 | 7.55 | 101.90 | 8.09 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.46 | 4.16 | 3.30 | 3.09 | 2.46 | 2.71 | 2.87 | 3.25 | 3.61 | 2.41 | 2.38 | 3.22 | 3.10 | 2.51 | 2.53 | 2.29 | 1.47 | 1.89 | 1.97 | 4.08 | 4.77 |
| — | +53.3% | +15.1% | -4.9% | -31.8% | +12.7% | +20.8% | +0.8% | +16.5% | -4.3% | -6.0% | +40.8% | +110.4% | +33.1% | +28.4% | -43.9% | -69.1% | -75.0% | +41.2% | +97.9% | +101.4% | |
| Quick Ratio | 2.34 | 3.85 | 3.06 | 2.95 | 2.34 | 2.59 | 2.70 | 3.07 | 3.42 | 2.27 | 2.22 | 2.99 | 2.95 | 2.38 | 2.39 | 2.18 | 1.38 | 1.62 | 1.76 | 3.72 | 4.44 |
| — | +48.8% | +13.4% | -3.8% | -31.7% | +14.3% | +21.5% | +2.4% | +15.8% | -4.7% | -7.0% | +37.0% | +114.0% | +47.0% | +35.5% | -41.2% | -69.0% | -77.3% | +79.4% | +135.7% | +118.8% | |
| Interest Coverage | -7.32 | -5.91 | -14.41 | -86.06 | -34.06 | -12.15 | 13.93 | -8.50 | 8.76 | -8.92 | -31.84 | -33.04 | -26.22 | — | -82.46 | -79.66 | -383.40 | -112.67 | -169.66 | -94.17 | -56.18 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WGS stock.
GeneDx Holdings Corp.'s current P/E is -14.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
GeneDx Holdings Corp.'s current operating margin is -2.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking GeneDx Holdings Corp.'s business trajectory between earnings reports.